Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients

British Journal of Cancer

Volumn 89, Issue 11, 2003, Pages 2062-2068

  Leonard, R C F ^a   Miles, D ^b,c   Thomas, R ^d,e   Nussey, F ^f  

^a SINGLETON HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d BEDFORD HOSPITAL NHS TRUST   (United Kingdom)

^e CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Adjuvant chemotherapy; Breast cancer; Dose intensity; Neutropenia

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE;

ADULT; AGED; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; HEALTH CARE DELIVERY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL AUDIT; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; UNITED KINGDOM;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GREAT BRITAIN; HUMANS; MIDDLE AGED; NEUTROPENIA;

EID: 0242287522     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601279     Document Type: Review

References (20)

1. American Society of Clinical Oncology (1994) Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 12: 2471-2508
2. American Society of Clinical Oncology (1996) Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 14: 1957-1960
3. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years follow-up. N Engl J Med 332: 901-906
4. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, Frei III E (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90: 1205-1211
5. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325: 164-170
6. de Graaf H, Willemse PH, Bong SB, Piersma H, Tjabbes T, van Veelen H, Coenen JL, de Vries EG (1996) Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. Oncology 53(4): 289-294
7. Dranitsaris G, Tran TM (1995) Economic analysis of toxicity secondary to anthracycline-based breast cancer chemotherapy. Eur J Cancer 31A(13-14): 2174
8. Early Breast Cancer Trialists' Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930-942
9. Engelsman E, Klijn JC, Rubens RD, Wildiers J, Beex LV, Nooji MA, Rotmensz N, Sylvester R (1991) "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Cancer Co-operative Group Phase III Trial (10808). Eur J Cancer 27: 966-970
10. Gurney H (1989) The problem of neutropenia resulting from cancer therapy. Clinician 7: 2-10
11. Hayes NA (2001) Analyzing current practice patterns: lessons from Amgen's Project ChemoInsight®. Oncol Nurs Forum 28(2 Suppl): 11-16
12. Hryniuk WM (1998) The importance of dose intensity in the outcome of chemotherapy. In Advance in Oncology, Hellman S, DeVita V, Rosenbergs (eds) pp 121-141. Philadelphia:Lippincott
13. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Dongsheng T (1998) Randomized trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 14: 2651-2658
14. Longo DL, Duffey PL, DeVita Jr VT, Wesley MN, Hubbard SM, Young RC (1991) The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 9: 2042-2051
15. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade III JL, Winn RJ, Wozniak AJ, Somerfield MR (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Growth Factors Expert Panel. J Clin Oncol 18: 3558-3585
16. Seifeldin RA, Schultz JS (1998) Economic impact of neutropenia in breast cancer. In Proceedings of the American Society of Clinical Oncology, 1998, Abstract 1613 (published)
17. Silber JH, Fridman M, DiPaola RS, Erder MH, Pauly MV, Fox KR (1998a) First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 16: 2392-2400
18. Silber JH, Fridman M, Shpilsky A, Even-Shoshan O, Smink DS, Jayaraman J, Fox KR, Pauly MV (1998b) Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. J Clin Oncol 16: 2435-2444
19. The French Adjuvant Study Group (2001) Benefit of a high dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with prognostic factors: 5-year follow-up results of a French adjuvant study group 05 randomized trial. J Clin Oncol 19: 602-611
20. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR, Ballow AC, Frei E, Henderson IE (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330: 1253-1259